Figure 6
Figure 6. PolyP inhibitors reverse the ability of platelet releasates to accelerate factor XI activation by thrombin. Initial rates of activation of 30nM human factor XI by 20nM human α-thrombin were determined in the presence of releasate prepared from TRAP-stimulated human platelets as described,11 normalized to the rate of factor XI activation without any added polyP inhibitor. Percent inhibition is plotted versus inhibitor concentration for the following: low MW polyethyleneimine (▴); generation 1.0 dendrimer (■); spermine (▵); PPXbd (●); or polymyxin B (□). Data are mean ± SE (n = 4). IC50 values calculated from these curves are given in the text. In the second stage of the assay, factor XIa levels were quantified, as previously described,11 by monitoring the rate of cleavage of the chromogenic substrate, L-Pyr-Pro-Arg-p-nitroanilide. At the concentrations used, none of the inhibitors altered the rate of hydrolysis of this substrate by factor XIa.

PolyP inhibitors reverse the ability of platelet releasates to accelerate factor XI activation by thrombin. Initial rates of activation of 30nM human factor XI by 20nM human α-thrombin were determined in the presence of releasate prepared from TRAP-stimulated human platelets as described,11  normalized to the rate of factor XI activation without any added polyP inhibitor. Percent inhibition is plotted versus inhibitor concentration for the following: low MW polyethyleneimine (▴); generation 1.0 dendrimer (■); spermine (▵); PPXbd (●); or polymyxin B (□). Data are mean ± SE (n = 4). IC50 values calculated from these curves are given in the text. In the second stage of the assay, factor XIa levels were quantified, as previously described,11  by monitoring the rate of cleavage of the chromogenic substrate, L-Pyr-Pro-Arg-p-nitroanilide. At the concentrations used, none of the inhibitors altered the rate of hydrolysis of this substrate by factor XIa.

Close Modal

or Create an Account

Close Modal
Close Modal